Sign In
AMPE.US

Ampio (AMPE) Shareholder Settlement

D. Colorado
Court
1:22-cv-02105
Case number
29 Dec 2020
Class period Start
03 Aug 2022
Class period End
Ampio (AMPE) agreed in principle to settle with investors to end claims over misrepresenting the efficacy of Ampion in treating individuals with inflammatory conditions.

In 2022, Ampio (AMPE) issued a letter to Shareholders covering the initial results of the investigation initiated on May 16, 2022.
  • Special Committee's primary findings include that certain former Ampio executive officers and senior staff were aware, at the time of the per-protocol interim analysis in March 2020, that the AP-013 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function;
  • These former Ampio executive officers and senior staff did not fully report the results of the AP-013 trial and the timing of unblinding of data from the AP-013 trial.
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.13
Filing date
17 August 2022
Lead Plaintiff Deadline
17 October 2022
Plaintiffs
Tao Wang, Christopher Kain
Attorneys
Faruqi & Faruqi LLP (New York, NY)
Defendants
Michael A. Martino, Michael Macaluso, Holli Cherevka, Dan Stokely, David Bar-Or, Philip H. Coelho, Richard B. Giles
Judge
Hon. William J. Martinez
Trades matching type
FIFO
Created by Stan Vick, Scout

Ampio Pharm

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formula...

    Ticker
    AMPE.US
    ISIN
    US03209T1097
    CIK
    1411906
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    9800 Mount Pyramid Court, Englewood, CO, United States, 80112